POLYMERIC SILVER NANOCARRIERS: INNOVATIVE DRUG DELIVERY STRATEGIES FOR ALZHEIMER’S DISEASE AND NEURODEGENERATIVE DISORDERS
DOI:
https://doi.org/10.22159/ijcpr.2026v18i2.8049Keywords:
Alzheimer's disease, Blood-brain barrier, Polymeric silver nanocarriers, Neurodegeneration, Nanomedicine, Targeted drug deliveryAbstract
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder marked by amyloid-β plaque accumulation, tau hyperphosphorylation, oxidative stress, neuroinflammation, and progressive cognitive impairment. The clinical effectiveness of conventional therapies is limited due to poor brain bioavailability, rapid systemic clearance, and the restrictive nature of the blood–brain barrier (BBB), resulting mainly in symptomatic relief rather than disease modification. In this context, polymeric silver nanocarriers (PSNs) have emerged as a promising nanotherapeutic approach for targeted and controlled drug delivery to the central nervous system. By integrating the antioxidant and anti-inflammatory properties of silver nanoparticles with the biocompatibility, stability, and controlled release characteristics of polymeric matrices such as PLGA, PEG, and chitosan, PSNs enable enhanced drug encapsulation, sustained release, and efficient BBB penetration through surface functionalization and receptor-mediated transport mechanisms. Preclinical in vitro and in vivo studies demonstrate that PSNs can effectively reduce amyloid-β aggregation, inhibit tau pathology, attenuate oxidative stress, and suppress neuroinflammatory responses, leading to improved neuronal survival and cognitive outcomes. Alternative delivery strategies, including intranasal and nose-to-brain routes, further improve therapeutic efficiency while minimizing systemic toxicity. Although challenges related to long-term safety, neurotoxicity, scalability, and regulatory approval remain, polymeric silver nanocarriers represent a versatile and multifunctional platform with significant potential for advancing disease-modifying therapies in Alzheimer’s disease.
Downloads
References
1. Lamptey RN, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022 Feb 6;23(3):1851. doi: 10.3390/ijms23031851, PMID 35163773.
2. Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018 Apr;10(4):a033118. doi: 10.1101/cshperspect.a033118, PMID 28716886.
3. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018 Jan 19;25(1):59-70. doi: 10.1111/ene.13439, PMID 28872215.
4. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019 Dec 2;14(1):32. doi: 10.1186/s13024-019-0333-5, PMID 31375134.
5. Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 1996 Apr;36(1):83-106. doi: 10.1146/annurev.pa.36.040196.000503, PMID 8725383.
6. Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood–brain barrier: structure regulation and drug delivery. Signal Transduct Target Ther. 2023 May 25;8(1):217. doi: 10.1038/s41392-023-01481-w, PMID 37231000.
7. Appelboom G, Detappe A, Lo Presti M, Kunjachan S, Mitrasinovic S, Goldman S. Stereotactic modulation of blood–brain barrier permeability to enhance drug delivery. Neuro Oncol. 2016 Dec;18(12):1601-9. doi: 10.1093/neuonc/now137, PMID 27407134.
8. Ahlawat J, Guillama Barroso G, Masoudi Asil S, Alvarado M, Armendariz I, Bernal J. Nanocarriers as potential drug delivery candidates for overcoming the blood–brain barrier: challenges and possibilities. ACS Omega. 2020 Jun 9;5(22):12583-95. doi: 10.1021/acsomega.0c01592, PMID 32548442.
9. Saraiva C, Praca C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release. 2016 Aug;235:34-47. doi: 10.1016/j.jconrel.2016.05.044, PMID 27208862.
10. Lee D, Minko T. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier. Pharmaceutics. 2021 Nov 30;13(12):2049. doi: 10.3390/pharmaceutics13122049, PMID 34959331.
11. Awad R, Avital A, Sosnik A. Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders. Acta Pharm Sin B. 2023 May;13(5):1866-86. doi: 10.1016/j.apsb.2022.07.003, PMID 37250152.
12. Mulvihill JJ, Cunnane EM, Ross AM, Duskey JT, Tosi G, Grabrucker AM. Drug delivery across the blood–brain barrier: recent advances in the use of nanocarriers. Nanomedicine (Lond). 2020 Jan 9;15(2):205-14. doi: 10.2217/nnm-2019-0367, PMID 31916480.
13. Tsou YH, Zhang XQ, Zhu H, Syed S, Xu X. Drug delivery to the brain across the blood–brain barrier using nanomaterials. Small. 2017 Nov 16;13(43):1701921. doi: 10.1002/smll.201701921, PMID 29045030.
14. Youssif KA, Haggag EG, Elshamy AM, Rabeh MA, Gabr NM, Seleem A. Anti-alzheimer potential metabolomic profiling and molecular docking of green synthesized silver nanoparticles of Lampranthus coccineus and Malephora lutea aqueous extracts. PLOS One. 2019 Nov 6;14(11):e0223781. doi: 10.1371/journal.pone.0223781, PMID 31693694.
15. Ramirez Acosta CM, Cifuentes J, Castellanos MC, Moreno RJ, Munoz Camargo C, Cruz JC. PH-responsive cell-penetrating core/shell magnetite/silver nanoparticles for the delivery of plasmids: preparation characterization and preliminary in vitro evaluation. Pharmaceutics. 2020 Jun 17;12(6):561. doi: 10.3390/pharmaceutics12060561, PMID 32560390.
16. Afzal O, Altamimi AS, Ather H, Sultana S, Almalki WH, Bharti P, Mir Najib Ullah SN. Nanomedicine in the management of Alzheimer’s disease: state-of-the-art. Biomedicines. 2023;11(6):1752. doi: 10.3390/biomedicines11061752.
17. Zhang QL, Fu BM, Zhang ZJ. Borneol a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability. Drug Deliv. 2017 Jan 1;24(1):1037-44. doi: 10.1080/10717544.2017.1346002, PMID 28687052.
18. Reitz C. Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis. 2012;2012:369808. doi: 10.1155/2012/369808, PMID 22506132.
19. Ju Y, Tam KY. Pathological mechanisms and therapeutic strategies for Alzheimer’s disease. Neural Regen Res. 2022;17(3):543-9. doi: 10.4103/1673-5374.320970, PMID 34380884.
20. Monteiro AR, Barbosa DJ, Remiao F, Silva R. Alzheimer’s disease: insights and new prospects in disease pathophysiology biomarkers and disease-modifying drugs. Biochem Pharmacol. 2023 May;211:115522. doi: 10.1016/j.bcp.2023.115522, PMID 36996971.
21. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: pathogenesis diagnostics and therapeutics. Int J Nanomedicine. 2019 Jul;14:5541-54. doi: 10.2147/IJN.S200490, PMID 31410002.
22. Wechsler ME, Ramirez JE, Peppas NA. 110th anniversary: nanoparticle mediated drug delivery for the treatment of Alzheimer’s disease: crossing the blood–brain barrier. Ind Eng Chem Res. 2019 Aug 21;58(33):15079-87. doi: 10.1021/acs.iecr.9b02196, PMID 32982041.
23. Bakota L, Brandt R. Tau biology and tau-directed therapies for Alzheimer’s disease. Drugs. 2016 Mar 4;76(3):301-13. doi: 10.1007/s40265-015-0529-0, PMID 26729186.
24. Chun W, Johnson GV. The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci. 2007;12(1):733-56. doi: 10.2741/2097, PMID 17127334.
25. Boutajangout A, Wisniewski T. Tau-based therapeutic approaches for Alzheimer’s disease a mini-review. Gerontology. 2014;60(5):381-5. doi: 10.1159/000358875, PMID 24732638.
26. Calvo Rodriguez M, Kharitonova EK, Bacskai BJ. Therapeutic strategies to target calcium dysregulation in Alzheimer’s disease. Cells. 2020 Nov 20;9(11):2513. doi: 10.3390/cells9112513, PMID 33233678.
27. Lafay Chebassier C, Paccalin M, Page G, Barc Pain S, Perault Pochat MC, Gil R. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer’s disease. J Neurochem. 2005 Jul 10;94(1):215-25. doi: 10.1111/j.1471-4159.2005.03187.x, PMID 15953364.
28. Zhang Z, Yang X, Song YQ, Tu J. Autophagy in Alzheimer’s disease pathogenesis: therapeutic potential and future perspectives. Ageing Res Rev. 2021 Dec;72:101464. doi: 10.1016/j.arr.2021.101464, PMID 34551326.
29. Liu J, Li L. Targeting autophagy for the treatment of Alzheimer’s disease: challenges and opportunities. Front Mol Neurosci. 2019 Aug 22;12:203. doi: 10.3389/fnmol.2019.00203, PMID 31507373.
30. Jantas D, Lason W. Preclinical evidence for the interplay between oxidative stress and RIP1-dependent cell death in neurodegeneration: state of the art and possible therapeutic implications. Antioxidants (Basel). 2021 Sep 24;10(10):1518. doi: 10.3390/antiox10101518, PMID 34679652.
31. Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS. 2012 Dec 9;9(1):23. doi: 10.1186/2045-8118-9-23, PMID 23140302.
32. Kutuzov N, Flyvbjerg H, Lauritzen M. Contributions of the glycocalyx endothelium and extravascular compartment to the blood–brain barrier. Proc Natl Acad Sci USA. 2018 Oct 2;115(40):E9429-38. doi: 10.1073/pnas.1802155115, PMID 30217895.
33. Singh SA, Vellapandian C. Structure of the blood brain barrier and its role in the transporters for the movement of substrates across the barriers. Curr Drug Metab. 2023 Aug 4;24(4):250-69. doi: 10.2174/1389200224666230608110349, PMID 37291784.
34. Ruck T, Bittner S, Meuth SG. Blood–brain barrier modeling: challenges and perspectives. Neural Regen Res. 2015;10(6):889-91. doi: 10.4103/1673-5374.158342, PMID 26199600.
35. Dong X. Current strategies for brain drug delivery. Theranostics. 2018;8(6):1481-93. doi: 10.7150/thno.21254, PMID 29556336.
36. Haumann R, Videira JC, Kaspers GJ, Van Vuurden DG, Hulleman E. Overview of current drug delivery methods across the blood–brain barrier for the treatment of primary brain tumors. CNS Drugs. 2020 Nov 23;34(11):1121-31. doi: 10.1007/s40263-020-00766-w, PMID 32965590.
37. Naqvi S, Panghal A, Flora SJ. Nanotechnology: a promising approach for delivery of neuroprotective drugs. Front Neurosci. 2020 Jun 9;14:494. doi: 10.3389/fnins.2020.00494, PMID 32581676.
38. Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R. Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB. Pharmaceutics. 2021 Jul 31;13(8):1183. doi: 10.3390/pharmaceutics13081183, PMID 34452143.
39. Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013 May 21;2013:238428. doi: 10.1155/2013/238428, PMID 25937958.
40. Pulgar VM. Transcytosis to cross the blood brain barrier new advancements and challenges. Front Neurosci. 2019 Jan 11;12:1019. doi: 10.3389/fnins.2018.01019, PMID 30686985.
41. Busquets MA, Espargaro A, Sabate R, Estelrich J. Magnetic nanoparticles cross the blood–brain barrier: when physics rises to a challenge. Nanomaterials (Basel). 2015 Dec 11;5(4):2231-48. doi: 10.3390/nano5042231, PMID 28347118.
42. Moura RP, Martins C, Pinto S, Sousa F, Sarmento B. Blood–brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology. Expert Opin Drug Deliv. 2019 Mar 4;16(3):271-85. doi: 10.1080/17425247.2019.1583205, PMID 30767695.
43. Roda F, Caraffi R, Picciolini S, Tosi G, Vandelli MA, Ruozi B. Recent advances on surface-modified GBM targeted nanoparticles: targeting strategies and surface characterization. Int J Mol Sci. 2023 Jan 27;24(3):2496. doi: 10.3390/ijms24032496, PMID 36768820.
44. Barar J, Rafi MA, Pourseif MM, Omidi Y. Blood–brain barrier transport machineries and targeted therapy of brain diseases. BioImpacts. 2016 Dec 5;6(4):225-48. doi: 10.15171/bi.2016.30, PMID 28265539.
45. Lajoie JM, Shusta EV. Targeting receptor-mediated transport for delivery of biologics across the blood–brain barrier. Annu Rev Pharmacol Toxicol. 2015 Jan 6;55(1):613-31. doi: 10.1146/annurev-pharmtox-010814-124852, PMID 25340933.
46. Van Schaik PE, Zuhorn IS, Baron W. Targeting fibronectin to overcome remyelination failure in multiple sclerosis: the need for brain- and lesion-targeted drug delivery. Int J Mol Sci. 2022 Jul 29;23(15):8418. doi: 10.3390/ijms23158418, PMID 35955549.
47. Sim TM, Tarini D, Dheen ST, Bay BH, Srinivasan DK. Nanoparticle-based technology approaches to the management of neurological disorders. Int J Mol Sci. 2020 Aug 23;21(17):6070. doi: 10.3390/ijms21176070, PMID 32842530.
48. Huang CL, Hsiao IL, Lin HC, Wang CF, Huang YJ, Chuang CY. Silver nanoparticles affect on gene expression of inflammatory and neurodegenerative responses in mouse brain neural cells. Environ Res. 2015 Jan;136:253-63. doi: 10.1016/j.envres.2014.11.006, PMID 25460644.
49. De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008 Jun;3(2):133-49. doi: 10.2147/ijn.s596, PMID 18686775.
50. Lin HC, Ho MY, Tsen CM, Huang CC, Wu CC, Huang YJ. From the cover: comparative proteomics reveals silver nanoparticles alter fatty acid metabolism and amyloid beta clearance for neuronal apoptosis in a triple cell coculture model of the blood–brain barrier. Toxicol Sci. 2017 Jul;158(1):151-63. doi: 10.1093/toxsci/kfx079, PMID 28460142.
51. Wong KH, Riaz MK, Xie Y, Zhang X, Liu Q, Chen H. Review of current strategies for delivering Alzheimer’s disease drugs across the blood–brain barrier. Int J Mol Sci. 2019 Jan 17;20(2):381. doi: 10.3390/ijms20020381, PMID 30658419.
52. Wong XY, Sena Torralba A, Alvarez Diduk R, Muthoosamy K, Merkoci A. Nanomaterials for nanotheranostics: tuning their properties according to disease needs. ACS Nano. 2020 Mar 24;14(3):2585-627. doi: 10.1021/acsnano.9b08133, PMID 32031781.
53. Hu L, Tao Y, Jiang Y, Qin F. Recent progress of nanomedicine in the treatment of Alzheimer’s disease. Front Cell Dev Biol. 2023 Jun 29;11:1228679. doi: 10.3389/fcell.2023.1228679, PMID 37457297.
54. Karimi M, Ghasemi A, Sahandi Zangabad P, Rahighi R, Moosavi Basri SM, Mirshekari H. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457-501. doi: 10.1039/C5CS00798D, PMID 26776487.
55. Kumar N, Desagani D, Chandran G, Ghosh NN, Karthikeyan G, Waigaonkar S. Biocompatible agarose-chitosan coated silver nanoparticle composite for soft tissue engineering applications. Artif Cells Nanomed Biotechnol. 2018 Apr 3;46(3):637-49. doi: 10.1080/21691401.2017.1337021, PMID 28639839.
56. Rocha CV, Goncalves V, Da Silva MC, Banobre Lopez M, Gallo J. PLGA-based composites for various biomedical applications. Int J Mol Sci. 2022 Feb 12;23(4):2034. doi: 10.3390/ijms23042034, PMID 35216149.
57. Karthivashan G, Ganesan P, Park SY, Kim JS, Choi DK. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug Deliv. 2018 Jan 1;25(1):307-20. doi: 10.1080/10717544.2018.1428243, PMID 29350055.
58. Mathur P, Jha S, Ramteke S, Jain NK. Pharmaceutical aspects of silver nanoparticles. Artif Cells Nanomed Biotechnol. 2018 Oct 31;46(Suppl 1):115-26. doi: 10.1080/21691401.2017.1414825, PMID 29231755.
59. Huang KS, Wang LS, Wang CY, Yang CH, Hsieh CL, Chen SY. Synthesis and anti-fungal effect of silver nanoparticlesandamp; ndash; chitosan composite particles. Int J Nanomedicine. 2015 Apr 1;10:2685-96. doi: 10.2147/IJN.S77410.
60. Bhattacharya T, Soares GA, Chopra H, Rahman MM, Hasan Z, Swain SS. Applications of phyto-nanotechnology for the treatment of neurodegenerative disorders. Materials (Basel). 2022 Jan 21;15(3):804. doi: 10.3390/ma15030804, PMID 35160749.
61. Ege D. Action mechanisms of curcumin in Alzheimer’s disease and its brain targeted delivery. Materials (Basel). 2021 Jun 16;14(12):3332. doi: 10.3390/ma14123332, PMID 34208692.
62. Fan S, Zheng Y, Liu X, Fang W, Chen X, Liao W. Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease. Drug Deliv. 2018 Jan 1;25(1):1091-102. doi: 10.1080/10717544.2018.1461955, PMID 30107760.
63. Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L. Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond. Transl Neurodegener. 2022 Dec 18;11(1):18. doi: 10.1186/s40035-022-00292-3, PMID 35300725.
64. Maiti P, Dunbar GL. Use of curcumin a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. Int J Mol Sci. 2018 May 31;19(6):1637. doi: 10.3390/ijms19061637, PMID 29857538.
65. Chung IM, Park I, Seung Hyun K, Thiruvengadam M, Rajakumar G. Plant-mediated synthesis of silver nanoparticles: their characteristic properties and therapeutic applications. Nanoscale Res Lett. 2016 Dec 28;11(1):40. doi: 10.1186/s11671-016-1257-4, PMID 26821160.
66. Karthikeyan A, Senthil N, Min T. Nanocurcumin: a promising candidate for therapeutic applications. Front Pharmacol. 2020 May 1;11:487. doi: 10.3389/fphar.2020.00487, PMID 32425772.
67. Bhaskar S, Tian F, Stoeger T, Kreyling W, De La Fuente JM, Grazu V. Multifunctional nanocarriers for diagnostics drug delivery and targeted treatment across blood–brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 2010 Dec 3;7(1):3. doi: 10.1186/1743-8977-7-3, PMID 20199661.
68. Cano A, Turowski P, Ettcheto M, Duskey JT, Tosi G, Sanchez Lopez E. Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges. J Nanobiotechnology. 2021 Apr 29;19(1):122. doi: 10.1186/s12951-021-00864-x, PMID 33926475.
69. Sukhanova A, Bozrova S, Sokolov P, Berestovoy M, Karaulov A, Nabiev I. Dependence of nanoparticle toxicity on their physical and chemical properties. Nanoscale Res Lett. 2018 Dec 7;13(1):44. doi: 10.1186/s11671-018-2457-x, PMID 29417375.
70. Begines B, Ortiz T, Perez Aranda M, Martinez G, Merinero M, Arguelles Arias F. Polymeric nanoparticles for drug delivery: recent developments and future prospects. Nanomaterials (Basel). 2020 Jul 19;10(7):1403. doi: 10.3390/nano10071403, PMID 32707641.
71. Shumbula NP, Nkabinde SS, Ndala ZB, Mpelane S, Shumbula MP, Mdluli PS. Evaluating the antimicrobial activity and cytotoxicity of polydopamine capped silver and silver/polydopamine core-shell nanocomposites. Arab J Chem. 2022 Jun;15(6):103798. doi: 10.1016/j.arabjc.2022.103798.
72. Simko M, Mattsson MO. Risks from accidental exposures to engineered nanoparticles and neurological health effects: a critical review. Part Fibre Toxicol. 2010;7(1):42. doi: 10.1186/1743-8977-7-42, PMID 21176150.
73. Gandhi S, Shastri DH, Shah J, Nair AB, Jacob S. Nasal delivery to the brain: harnessing nanoparticles for effective drug transport. Pharmaceutics. 2024 Apr 1;16(4):481. doi: 10.3390/pharmaceutics16040481, PMID 38675142.
74. Dighe S, Jog S, Momin M, Sawarkar S, Omri A. Intranasal drug delivery by nanotechnology: advances in and challenges for Alzheimer’s disease management. Pharmaceutics. 2023 Dec 29;16(1):58. doi: 10.3390/pharmaceutics16010058, PMID 38258068.
75. Alexander A, Saraf S. Nose-to-brain drug delivery approach: a key to easily accessing the brain for the treatment of Alzheimer’s disease. Neural Regen Res. 2018;13(12):2102-4. doi: 10.4103/1673-5374.241458, PMID 30323136.
76. Al-azzawi S, Masheta D, Guildford AL, Phillips G, Santin M. Dendrimeric poly(epsilon-lysine) delivery systems for the enhanced permeability of flurbiprofen across the blood-brain barrier in Alzheimer’s disease. Int J Mol Sci. 2018 Oct 18;19(10):3224. doi: 10.3390/ijms19103224, PMID 30340406.
77. Sonvico F, Clementino A, Buttini F, Colombo G, Pescina S, Staniscuaski Guterres S. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics. 2018 Mar 15;10(1):34. doi: 10.3390/pharmaceutics10010034, PMID 29543755.
78. Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014 Mar 9;21(2):75-86. doi: 10.3109/10717544.2013.838713, PMID 24102636.
79. Islam SU, Shehzad A, Ahmed MB, Lee YS. Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders. Molecules. 2020;25(8):1929. doi: 10.3390/molecules25081929, PMID 32326318.
80. Prabhu S, Poulose EK. Silver nanoparticles: mechanism of antimicrobial action synthesis medical applications and toxicity effects. Int Nano Lett. 2012 Dec 29;2(1):32. doi: 10.1186/2228-5326-2-32.
81. Del Amo L, Cano A, Ettcheto M, Souto EB, Espina M, Camins A. Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer’s disease. Appl Sci. 2021 May 10;11(9):4305. doi: 10.3390/app11094305.
82. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012 Jun 10;14(2):282-95. doi: 10.1208/s12248-012-9339-4, PMID 22407288.
83. Oberdorster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med. 2010 Jan 11;267(1):89-105. doi: 10.1111/j.1365-2796.2009.02187.x, PMID 20059646.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Himanshu Kinkar, DIVYANSH DHARPURE, Dr. Dhanashri Tumme
This work is licensed under a Creative Commons Attribution 4.0 International License.